BJR
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
British Journal of Radiology (2008) 81, S28-S35
© 2008 British Institute of Radiology
doi: 10.1259/bjr/27723093
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by McCluskey, A G
Right arrow Articles by Mairs, R J
PubMed
Right arrow PubMed Citation
Right arrow Articles by McCluskey, A G
Right arrow Articles by Mairs, R J
British Journal of Radiology 81 (2008),S28-S35 ©2008 The British Institute of Radiology

Full paper

Experimental treatment of neuroblastoma using [131I]meta-iodobenzylguanidine and topotecan in combination

A G McCluskey, PhD1, M Boyd, PhD1, S L Pimlott, PhD2, J W Babich, PhD3, M N Gaze, MD, PhD4 and R J Mairs, DSc1,5

1 Targeted Therapy Group, Division of Cancer Sciences, Faculty of Medicine, University of Glasgow, Cancer Research UK Beatson Laboratories, Garscube Estate, Glasgow G61 1BD, 2 Radionuclide Dispensary, Western Infirmary, Glasgow G11 6NT UK, 3 Molecular Insight Pharmaceuticals, Inc., Cambridge, MA 02142, USA, 4 University College London Hospitals NHS Foundation Trust, Middlesex Hospital, Mortimer Street, London W1T 3AA,, 5 Department of Child Health, University of Glasgow, Cancer Research UK Beatson Laboratories, Garscube Estate, Glasgow G61 1BD, UK

Correspondence: R J Mairs, Targeted Therapy Group, University of Glasgow, Cancer Research UK Beatson Laboratories, Garscube Estate, Glasgow G61 1BD, UK. E-mail: r.mairs{at}beatson.gla.ac.uk

The radiopharmaceutical [131I]meta-iodobenzylguanidine ([131I]MIBG) and the topoisomerase I inhibitor topotecan are both effective as single-agent treatments of neuroblastoma. Our purpose was to assess the therapeutic potential of [131I]MIBG and topotecan in combination using SK-N-BE(2c) neuroblastoma cells and UVW/NAT glioma cells expressing the noradrenaline transporter transgene. Topotecan treatment was given (i) before, (ii) after or (iii) simultaneously with [131I]MIBG. DNA fragmentation was evaluated by comet assay and cell cycle redistribution was determined by fluorescence-activated cell sorting. Combination index analysis indicated that delivery schedules (ii) and (iii) were more effective than schedule (i) with respect to clonogenic cell kill. Similarly, significant DNA damage was observed following treatment schedules (ii) and (iii) (p <0.005), but not (i). Prior exposure to topotecan did not significantly enhance [131I]MIBG uptake in athymic mice bearing tumour xenografts. We conclude that the enhancement of the efficacy of [131I]MIBG by combining it with topotecan was the result of inhibition of DNA damage repair rather than an increase in expression of the noradrenaline transporter by tumour.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
BJR DMFR IMAGING  ALL BIR JOURNALS 
Copyright © 2008 by the British Institute of Radiology.